{
  "docId": "019de073-d2da-762c-9a26-b97a59cfec30",
  "docSlug": "f7af69768ee002be4e2317aa5e807561",
  "documentTitle": "Revelation Biosciences | Investor Presentation Deck | 18 slides",
  "authorId": "revelation-biosciences",
  "authorName": "Revelation Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 18,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes a biological pathway diagram illustrating the mechanism of action of PHAD on TLR4 pathways.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-d2da-762c-9a26-b97a59cfec30/13",
  "deckHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30",
  "deckJsonHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30.json",
  "deckAnchorHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.48,
        "y": 0.12
      },
      "kind": "image",
      "text": "Biological pathway diagram showing TLR stimulation and the effect of PHAD on inflammation and ROS.",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed041449-3a09-4ead-b1cc-972a24cc0c91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.52,
        "y": 0.68
      },
      "kind": "list",
      "text": "Next Steps: Nonclinical GROUCHO study examining effect of PHAD as a treatment for AKI and CKD in progress: UUO Model evaluating levels of inflammation and fibrosis. Data expected Q4 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24b8e551-471b-4d65-85d3-857e9039de56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.02,
        "y": 0.68
      },
      "kind": "list",
      "text": "Market: According to CDC more than 1 in 7, or 15% of US adults are estimated to have CKD. CDC estimates 37 million adults in US have CKD with an annual estimated Medicare cost of $87 billion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ecf3bdd-0452-4589-b01e-ac2c74b24090",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.02,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Scientific Rationale: Chronic organ disease (such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH), and myocarditis) are propagated by inflammation, followed by fibrosis, and ultimately loss of organ function. Stimulation of TLR4 via the TRIF pathway with PHAD downregulates the inflammatory response, which reduces the generation of reactive oxidative species (ROS), reducing tissue damage and halting tissue fibrotic processes.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d11f8ea-b563-465f-bd10-fd2e351eb923",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "REVTx-300 Program Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b8f10f2-9ef7-41b0-88db-30c8d159310b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ddb801f2-055a-4025-afbb-fdf1d8197554",
      "evidence": "This slide contains a list of bullet points, which is a common way to present information in a list format.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 4,
      "beatId": "2182d072-e6b9-49a0-b466-5a839998139b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-15 describe various solutions, including PHAD, REVTx-100, REVTx-200, and REVDx-501.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f450b0af-f83a-4370-8b16-ab5011fb13d6",
      "evidence": "Slides 4-15 describe PHAD and its applications.",
      "position": 1,
      "objective": "Why is PHAD a well-defined TLR4 agonist with multiple potential applications?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}